The investigation of the amounts and expressions of epidermal growth factor, epidermal growth factor receptor, and epidermal growth factor receptor gene polymorphisms in acne vulgaris

Aydingoz I. E., Demirci G. T., Agirbasli D., Oz-Arslan D., Yenmis G.

JOURNAL OF COSMETIC DERMATOLOGY, vol.20, no.1, pp.346-351, 2021 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 20 Issue: 1
  • Publication Date: 2021
  • Doi Number: 10.1111/jocd.13498
  • Journal Name: JOURNAL OF COSMETIC DERMATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, MEDLINE
  • Page Numbers: pp.346-351
  • Keywords: acne vulgaris, epidermal growth factor, epidermal growth factor receptor, etiology, gene expression, FACTOR EGF SERUM, SEBACEOUS GLANDS, SKIN TOXICITY, IMPROVEMENT, SCARS
  • Istanbul University-Cerrahpasa Affiliated: Yes

Abstract

Background Epidermal growth factor receptor inhibitors (EGFRI) used in cancer chemotherapy cause acneiform folliculitis in 70%-100% of patients in a dose-dependent manner. Acneiform folliculitis is considered to be caused by an inflammatory process due to follicular hyperkeratosis and subsequently a set of changes both in epidermis and hair follicles as a result of epidermal growth factor receptor (EGFR) blockade. Both acne vulgaris and acneiform folliculitis due to EGFRIs show similar changes in the pilosebaceous unit. Furthermore, in both groups of patients, topical application of recombinant human epidermal growth factor (EGF) has been reported to improve the disease.